mgh_logo

Harvard-Medical-School-logo

Generic filters

antidepressants

SSRIs and Pregnancy: Evaluating New Reproductive Safety Data

Over the past 15 years, multiple studies have addressed the reproductive safety of various antidepressants. Data on the overall teratogenicity of SSRIs has come from relatively small prospective observational studies, larger international birth registries, managed health care databases, and case series; these data have cumulatively supported the reproductive safety of fluoxetine and certain other SSRIs. In a recent meta-analysis including 1774 antidepressant-exposed infants, first trimester exposure to SSRIs was not associated with an increased risk of major malformations above the baseline of 2%-3% seen in the general population (Einarson & Einarson, 2005). The bulk of the data thus far has suggested that SSRIs are not major teratogens; however, concerns about the potential teratogenicity of SSRIs were first raised in 2005 when several preliminary studies suggested that paroxetine may be associated with a small increase in risk of congenital abnormalities.

By |2015-08-11T10:55:05-04:00March 31st, 2008|Antidepressants, Outcomes, Pregnancy & Medications|Comments Off on SSRIs and Pregnancy: Evaluating New Reproductive Safety Data
Read More

Paroxetine CR May Be Helpful for Menopausal Women Discontinuing Hormone Therapy

Estrogen was first approved by the FDA for the treatment of menopausal symptoms in 1942, and for many decades estrogen replacement therapy had been widely prescribed for peri- and post-menopausal women. In 2002, however, data from the Women’s Health Initiative (WHI) suggested that hormonal therapy may be associated with an increased risk of breast cancer and cardiovascular disease. These findings have led to a dramatic decrease in the use of hormone replacement therapy (HRT), with many women abruptly discontinuing its use.

By |2015-07-28T10:53:58-04:00November 12th, 2007|Menopausal Symptoms, Treatment, Vasomotor Symptoms|Comments Off on Paroxetine CR May Be Helpful for Menopausal Women Discontinuing Hormone Therapy
Read More

SSRIs and Pregnancy: Putting the Risks into Perspective

Depression is common during pregnancy, affecting 10% to 15% of women. While psychotherapy is an attractive option for the treatment of depression during pregnancy, all women do not respond to this intervention and many require pharmacotherapy. Thus far, no antidepressants have yet been approved by the FDA for use during pregnancy. Although data accumulated over the past 30 years suggest that certain medications, including the serotonin reuptake inhibitors (SSRIs), may be used safely during pregnancy, several new studies have raised concerns regarding the use of these medications during pregnancy.

By |2015-07-28T10:29:44-04:00October 7th, 2007|Pregnancy & Medications|Comments Off on SSRIs and Pregnancy: Putting the Risks into Perspective
Read More

Antidepressant-Induced Sexual Side Effects

A recent article published in Psychiatric Times reviews options for the management of antidepressant-induced sexual dysfunction. According to this review, sexual side effects may occur in 40% to 70% of patients treated with serotonin reuptake inhibitors (SRIs) and is a common reason for poor compliance with treatment and eventual discontinuation. When sexual side effects occur, they tend to emerge early, are persistent, and rarely resolve spontaneously.

By |2015-07-16T14:56:44-04:00October 1st, 2007|Antidepressants, General, Sexual Health|Comments Off on Antidepressant-Induced Sexual Side Effects
Read More

Duloxetine for the Treatment of Menopausal Symptoms and Mood in Postmenopausal Women

Depression is common in postmenopausal women suffering from menopausal vasomotor symptoms (hot flushes, night sweats) and insomnia. While estrogen replacement therapy may alleviate these symptoms and may also have a positive impact on mood, the use of estrogen has declined over recent years. There has been great interest in finding alternative strategies for the management of menopausal symptoms, and recent data suggest that selective serotonin reuptake inhibitor antidepressants (SSRIs) and the serotonin norepinephrine reuptake inhibitor (SNRI), venlafaxine, may be effective for the treatment of depression and vasomotor symptoms in peri- and postmenopausal women. In a study presented at the annual meeting of the American Psychiatric Association, Dr. Hadine Joffe and her colleagues at the Center of Women’s Mental Health presented data on the use of duloxetine (Cymbalta), a new SNRI, for the treatment of mood, vasomotor symptoms, and insomnia in postmenopausal women.

By |2015-07-28T10:00:40-04:00July 30th, 2006|Depressive Disorders, Medication, Menopausal Symptoms, Treatment, Vasomotor Symptoms|Comments Off on Duloxetine for the Treatment of Menopausal Symptoms and Mood in Postmenopausal Women
Read More

Use of Paxil during Pregnancy

Q. I have taken Paxil for about six years for depression and obsessive-compulsive disorder. I have tried several times to stop the medication but the symptoms come back within a few weeks of stopping the medication. My husband and I are now planning a pregnancy, and my obstetrician tells me that I cannot take Paxil during pregnancy. Are there any other options?

By |2015-07-28T09:53:02-04:00April 24th, 2006|Antidepressants, Outcomes, Pregnancy & Medications, Risk of Malformations|Comments Off on Use of Paxil during Pregnancy
Read More

Withdrawal Symptoms in Newborns Exposed to SSRIs

A recent report suggests that newborns exposed to selective serotonin reuptake inhibitors (SSRI) antidepressants such as Prozac, Zoloft, Celexa and Paxil may be at risk for developing withdrawal symptoms after delivery (Levinson-Castiel 2005). However, the investigators also noted that the symptoms usually disappeared within 48 hours and did not require medical intervention.

By |2015-07-28T09:51:11-04:00April 24th, 2006|Antidepressants, Neonatal Symptoms, Outcomes, Pregnancy & Medications|Comments Off on Withdrawal Symptoms in Newborns Exposed to SSRIs
Read More

SSRIs and Neonatal Outcomes: A Population-Based Study from Finland

Literature accumulated over the last decade supports the use of certain selective serotonin reuptake inhibitors (SSRIs) and the older tricyclic antidepressants during pregnancy, indicating no increased risk of congenital malformation in children exposed to these medications during the first trimester of pregnancy. Still, questions remain regarding the purported risk for "toxicity" in newborns exposed to antidepressants around the time of labor and delivery. Several recent studies have suggested that exposure to SSRIs at the time of delivery may be associated with poor perinatal outcomes (Casper 2003, Laine 2003, Simon 2002, Zeskind and Stephens 2004) and prompted the FDA to include warnings in the packaging inserts regarding the use of certain antidepressants, including the selective serotonin reuptake inhibitors (SSRIs) and venlafaxine (Effexor), during pregnancy. These studies have been reviewed previously on the CWMH website (Newsletters Fall 2004 and Spring 2005).

By |2015-07-23T14:51:24-04:00January 24th, 2006|Antidepressants, Neonatal Symptoms, Pregnancy & Medications|Comments Off on SSRIs and Neonatal Outcomes: A Population-Based Study from Finland
Read More
Copyright 2026 MGH Center for Women's Mental Health | All Rights Reserved
Go to Top